74056
document
Lithium and granulocytopenia during induction therapy of acute myelogenous leukemia . Twenty-seven patients receiving a standard cytosine arabinoside and daunorubicin regimen as induction of reinduction therapy of acute myelogenous leukemia were randomly assigned to receive lithium carbonate , 300 mg t.i.d. , or no lithium . Treatment groups were comparable with respect to age and baseline granulocyte counts . All patients developed granulocyte nadirs below 100/cu mm . By actuarial analysis , the median duration of granulocytopenia , less than 1000/cu mm , was 16.0 days in the lithium group and 24.6 days in the no-lithium group , p = 0.013 . The median duration of granulocytes less than 500/cu mm also favored the lithium group but only approached statistical significance : 14.0 days versus 20.5 days , p = 0.054 . Lithium levels between 0.5 and 1.0 meq/liter were easily maintained in 11 of 12 patients receiving lithium , 300 mg t.i.d. , and toxicity directly attributable to lithium was not observed . Despite the shortened duration of neutropenia , the incidence of infections and the rate of remission were not affected .
74057
Intervention_Pharmacological
Lithium
74058
Intervention_Pharmacological
standard cytosine arabinoside
74059
Intervention_Pharmacological
daunorubicin regimen
74060
Intervention_Pharmacological
lithium carbonate , 300 mg t.i.d.
74061
Intervention_Pharmacological
no lithium
74062
Intervention_Pharmacological
lithium
74063
Intervention_Pharmacological
no-lithium
74064
Intervention_Pharmacological
lithium
74065
Intervention_Pharmacological
Lithium
74066
Intervention_Pharmacological
lithium
74067
Intervention_Pharmacological
lithium
74068
Outcome_Physical
granulocyte nadirs
74069
Outcome_Physical
median duration of granulocytopenia
74070
Outcome_Physical
median duration of granulocytes
74071
Outcome_Physical
Lithium levels between 0.5 and 1.0 meq/liter
74072
Outcome_Other
toxicity
74073
Outcome_Physical
shortened duration of neutropenia
74074
Participant_Condition
acute myelogenous leukemia .